Vanguard Group Inc. Reduces Stock Holdings in Xencor, Inc. $XNCR

Vanguard Group Inc. lowered its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 17.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,103,758 shares of the biopharmaceutical company’s stock after selling 1,520,616 shares during the quarter. Vanguard Group Inc. owned approximately 0.10% of Xencor worth $83,327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. JPMorgan Chase & Co. raised its stake in Xencor by 21.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 401,501 shares of the biopharmaceutical company’s stock worth $4,710,000 after acquiring an additional 71,494 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Xencor by 14.7% during the third quarter. Public Sector Pension Investment Board now owns 278,227 shares of the biopharmaceutical company’s stock worth $3,264,000 after purchasing an additional 35,575 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in shares of Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 2,156 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Xencor by 114.3% during the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 2,105 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Xencor by 28.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 123,138 shares of the biopharmaceutical company’s stock valued at $1,444,000 after purchasing an additional 27,393 shares during the last quarter.

Xencor Stock Performance

Shares of XNCR opened at $11.16 on Friday. The stock has a market capitalization of $818.47 million, a P/E ratio of -9.00 and a beta of 0.95. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69. The company’s fifty day moving average is $12.87 and its two-hundred day moving average is $12.90.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. The business’s quarterly revenue was down 46.6% compared to the same quarter last year. On average, sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insider Buying and Selling

In other Xencor news, CEO Bassil I. Dahiyat sold 6,758 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total transaction of $80,420.20. Following the transaction, the chief executive officer owned 567,792 shares in the company, valued at approximately $6,756,724.80. The trade was a 1.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 2,663 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total value of $31,689.70. Following the transaction, the vice president directly owned 270,451 shares of the company’s stock, valued at approximately $3,218,366.90. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 198,657 shares of company stock worth $3,080,057 in the last ninety days. 4.76% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

XNCR has been the topic of several research analyst reports. Wall Street Zen lowered Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Royal Bank Of Canada raised their target price on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. reduced their price target on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Wedbush reiterated an “outperform” rating and set a $26.00 price target on shares of Xencor in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald lifted their price objective on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Xencor reported an EPS beat for the latest quarter and retains a strong liquidity position (high current/quick ratios), which cushions near‑term financing risk and supports ongoing R&D programs. MarketBeat: Xencor company page
• Neutral Sentiment: CEO Bassil Dahiyat disclosed a sale of 6,758 shares at about $11.90 (roughly $80k). The sale reduced his stake by ~1.18% and may reflect routine diversification rather than a company-specific signal. SEC Form 4: CEO sale
• Negative Sentiment: Reported royalty rift: Alexion has cut off U.S. royalty payments to Xencor tied to Ultomiris, and Xencor said it is revising its Ultomiris royalty revenue forecast — a direct hit to near‑term revenue and the main catalyst for the share decline. Benzinga: Royalty rift report Company announcement: royalty forecast change
• Negative Sentiment: Additional insider sales: SVP Celia Eckert and VP John Desjarlais sold shares the same day (small percent reductions of their holdings). The cluster of insider sales has heightened investor concern about insider timing and added to negative sentiment. InsiderTrades: insider sale report

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.